formulated as [R 2 Sn(HL) 2 ] (a), and the arylhydroxamato/arylcarboxylato mixed-ligand complexes [R 2 Sn(HL)(L )] (b), were prepared and characterized by FT-IR, 1 H, 13 C and 119 Sn NMR spectroscopies, elemental analyses and melting point measurements. X-ray diffraction analysis was also carried out for the complex [Me 2 Sn{3,4-F 2 C 6 H 3 C(O)NHO} 2 ], 1a. These compounds exhibit in vitro cytotoxic activities towards human leukemic promyelocites HL-60, BGC-823, BEL-7402 and KB cell lines which, in some cases, are identical to, or even higher than, that of cisplatin. The type, position and number of the X substituents in the phenyl ring play a role in the cytotoxic activity, and complex 8a, with its 2,6-difluorobenzohydroxamato ligand, is highly active against all tumor cells. A tentative structure-activity relationship is also described. Mononuclear diorganotin(IV) complexes with arylhydroxamates 923 2C 6 H 3 ), 0.94 [s, 2CH 3 , R-Sn, 2 J(Sn-H) = 80 Hz] ppm. 13 C NMR (d 6 -DMSO): δ = 169.2 (CO), 157.2, 155.4, 130.6, 114.0, 112.3 and 102.1 (C arom ), 6.4 (CH 3 , R-Sn) ppm.